Clinical Trials Logo

Clinical Trial Summary

A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation


Clinical Trial Description

A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with SCID undergoing blood stem cell transplantation. Blood Stem Cell transplantation offers the only potentially curative therapy for SCID. The biological conditioning regimen, JSP191, is an antibody that binds to CD117. CD117 is the receptor for Stem Cell Factor on blood forming cells. CD117 binding to Stem Cell Factor is critical for survival and maintenance of blood forming stem cells. The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells. In the absence of CD117/Stem Cell Factor binding, hematopoietic stem cells that are currently occupying the bone marrow niches in SCID patients are depleted. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02963064
Study type Interventional
Source Jasper Therapeutics, Inc.
Contact Clinical Trials Jasper Therapeutics, Inc.
Phone 650-549-1270
Email ClinicalTrials@JasperTherapeutics.com
Status Recruiting
Phase Phase 1/Phase 2
Start date March 20, 2017
Completion date August 2027

See also
  Status Clinical Trial Phase
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Completed NCT01953016 - Participation in a Research Registry for Immune Disorders
Recruiting NCT03619551 - Conditioning SCID Infants Diagnosed Early Phase 2
Enrolling by invitation NCT01346150 - Patients Treated for SCID (1968-Present)